When monocytes were stimulated with IFN-γ alone MCP-1 secretion was not notably affected (Fig. 3c). However, when IFN-γ and PAR2-cAP were used together, MCP-1 secretion was enhanced significantly (1686 ± 335 pg/ml versus 271 ± 60 pg/ml GSK3235025 datasheet in samples treated by PAR2-cAP alone) (Fig. 3c). We next investigated which intracellular signalling molecules were involved in the effects of PAR2 agonist on MCP-1 secretion by human neutrophils, when this agonist was applied alone or in combination

with IFN-γ. In these experiments, we investigated the effects of the inhibitors of different intracellular signalling molecules: rottlerin (inhibits PKCδ), LY294002 (inhibits PI3 kinase), SB203580 (inhibits p38 kinase), and JAK inhibitor I pyridone 6 (inhibits JAKs). Experiments were performed with neutrophils treated for 28 hr with PAR2 agonist alone (PAR2-cAP 1 × 10−4 m) or in combination with IFN-γ (100 ng/ml), Gemcitabine concentration because the maximum effect on the MCP-1 secretion was revealed at that time-point. We found that rottlerin and LY294002 each completely

abolished the effect of co-application of PAR2-cAP and IFN-γ on MCP-1 release by human neutrophils (Fig. 4a). These results indicate the crucial role of PI3 kinase and PKCδ in enhancing MCP-1 secretion after co-stimulation of human neutrophils with PAR2-cAP and IFN-γ. In addition, treating neutrophils with either pyridine 6 or SB203580 only weakened the effect of PAR2-cAP and IFN-γ on MCP-1 secretion, which shows that p38 kinase and JAKs are involved in the combined action of both agonists (Fig. 4a). We also examined which intracellular signalling molecules are

involved in the enhanced secretion of MCP-1 by human neutrophils after treatment with PAR2-cAP alone (Fig. 4b). For these experiments, rottlerin, LY294002, SB203580 and pyridine 6 were used to check whether PI3 kinase, PKCδ, p38 kinase and JAKs were involved in the solo effect of PAR2 agonist on MCP-1 secretion by neutrophils. Rottlerin, LY294002 and SB203580 abolished PAR2-cAP-induced MCP-1 secretion (Fig. 4b), indicating a crucial role of PI3 kinase, p38 kinase and PKCδ on the effect of PAR2 stimulation. Dapagliflozin However, pyridine 6 did not significantly affect the changes in MCP-1 release, indicating that JAKs do not participate in the effect induced by PAR2 agonist alone (Fig. 4b). We also investigated whether rottlerin (inhibits PKCδ), LY294002 (inhibits PI3 kinase), SB203580 (inhibits p38 kinase), and JAK inhibitor I pyridone 6 (inhibits JAKs) affected the induction of MCP-1 secretion after stimulation of human monocytes with PAR2-cAP and IFN-γ (Fig. 5a). Experiments were performed with monocytes treated with PAR2-cAP together with IFN-γ for 28 hr.